Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 7/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.56 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.56 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.56 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.53 |
| ▸ | ATG7 | O95352 | 3/20 | 0.49 |
| ▸ | UBA6 | A0AVT1 | 1/20 | 0.49 |
| ▸ | UBA7 | P41226 | 1/20 | 0.49 |
| ▸ | NAE1 | Q13564 | 1/20 | 0.49 |
| ▸ | UBA3 | Q8TBC4 | 1/20 | 0.49 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17875220 | 0.86 | SLC29A1 (0.60) | ATG7NAE1UBA3ADORA3 | |
| SCHEMBL1795458 | 0.86 | P2RY12 (0.76) | P2RY12P2RY2P2RY1P2RY6BMPR1B | |
| SCHEMBL10186161 | 0.86 | SLC29A1 (0.60) | ATG7NAE1UBA3ADORA3 | |
| SCHEMBL1796246 | 0.86 | SLC29A1 (0.60) | ATG7NAE1UBA3ADORA3 | |
| SCHEMBL18630490 | 0.86 | P2RY12 (0.53) | P2RY12P2RY2P2RY1P2RY6BMPR1B | |
| SCHEMBL23080221 | 0.84 | NAE1 (0.60) | ATG7UBA6UBA7NAE1UBA3 | |
| SCHEMBL5583969 | 0.83 | P2RY12 (0.48) | P2RY12P2RY2P2RY1P2RY6ADORA3 | |
| SCHEMBL20621926 | 0.83 | ATG7 (0.44) | ATG7UBA6UBA7NAE1UBA3 | |
| SCHEMBL1795120 | 0.83 | DNPH1 (0.54) | P2RY1ATG7 | |
| SCHEMBL23080199 | 0.81 | SLC29A1 (0.49) | ATG7UBA6UBA7NAE1UBA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | P2RY12 4362/4885P2RY2 3908/4885P2RY1 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.